Michael R. Kurman - Michael Kurman Consulting, LLC

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 32 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract CT172: A Phase 1, Open-Label, Dose-Escalation Study of PRT1419, a Selective Induced Myeloid Leukemia Cell Differentiation Protein (MCL-1) Inhibitor, in Patients (pts) with Advanced/metastatic Solid Tumors

Gerald S. Falchook,Manish R. Patel,Meredith McKean,Alexander Philipovskiy,Rachel Chiaverelli,William Sun,Michael J. Fossler,William Novotny,Michael R. Kurman,Sarah Rowe,Deborah Hunter,Mohammed M. Milhem

Cancer researchno. 8_Supplement (2023): CT172-CT172

引用0浏览0引用

SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, IN COMBINATION WITH PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: RESULTS FROM A PHASE 2 STUDY

Jason Valent,Michaela Liedtke,Jeffrey Zonder,John Silowsky,Michael Kurman,Eileen Daniel,Janet Jobes,Mark Harnett,Amit Bhattacharyya,Candida Cristina Quarta,Julia Catini,Jessica Raviwong,Michael Spector, Susan Sobolov

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGYno. 9 (2022): 305-305

引用2浏览0引用

Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis

Ashutosh D. Wechalekar,John Silowsky,Eileen Daniel,Mark Harnett,Michael Spector,Susan B. Sobolov,Candida Cristina Quarta,Michael R. Kurman,Mark Tulchinskiy,Amit Bhattacharyya,Michaela Liedtke

Blood（2021）

引用2浏览0引用

Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia

Mark J. Levis,Catherine Choy Smith,Alexander E. Perl,Gary J. Schiller,Amir Tahmasb Fathi,Gail J. Roboz,Eunice S. Wang,Jessica K. Altman,Makoto Ando,Takeaki Suzuki,Ruth Ann Subach,Gary Maier,Timothy Madden,Mary Johansen,Kin Cheung,Michael R. Kurman

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用10浏览0引用

A Phase 1/2a, Open-Label, Multicenter Study of Intramuscular (IM) Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)

Tim Warneke,Michael R. Kurman,Robert Dreicer,Daniel J. George,Neal Shore,William Douglas Figg, Robert Schotzinger,William R. Moore

Journal of clinical oncologyno. 15_suppl (2021): TPS5090-TPS5090

引用0浏览0引用

Safety and Tolerability of Cael-101 in Combination with Anti-Plasma Cell Dyscrasia Therapy in Patients with AL Amyloidosis: 1-Year Results from an Open-Label Phase 2 Trial

Jason Valent,Jeffrey A. Zonder,Michaela Liedtke,John Silowsky,Michael R. Kurman,Eileen Daniel,Janet Jobes,Mark Harnett,Jessica Raviwong,Michael Spector,Susan B. Sobolov

Blood（2021）

引用3浏览0引用

Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy

Jason Valent,John Silowsky,Michael R. Kurman,Eileen Daniel,Janet Jobes,Mark Harnett,Sherry Fada,Michael Spector,Kathleen Stefunek, Heather Staley,Kristen Schlueter,Christy J. Samaras,Faiz Anwer,Jack Khouri,Jeffrey A. Zonder,Michaela Liedtke,Susan B. Sobolov

Blood（2021）

引用2浏览0引用

1006P ACE1702, a First-in-class, Off-the-shelf, Selected Natural Killer Cell [onk] Product Using Antibody Cell Conjugation Technology [ACC], with Pre-Clinical and Early Clinical Activity in HER2 < 3+ Tumors

Sarina A. Piha‐Paul,Devalingam Mahalingam, M. F. Mulcahy,Aparna Kalyan,H-K. Li, Enhao Wu,Michael R. Kurman, S. Lee, Yi Lin,S-W. Tang, C-W. Hsiao, J. Pan,Sheng‐Hsuan Chien

Annals of oncology（2021）

引用1浏览0引用

Cael-101 is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (cybord): A Phase 2 Dose-Finding Study (NCT04304144)

Jason Valent,John Silowsky,Michael R. Kurman,Eileen Daniel,Janet Jobes,Mark Harnett, Margaret Ziola, Jessica Roviwong,Sherry Fada,Michael Spector,Susan B. Sobolov

Blood（2020）

引用10浏览0引用

The AIM-HN and SEQ-HN Study: A Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with Hras Mutations (AIM-HN) and the Impact of Hras Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Robert Haddad,Kevin Joseph Harrington,Lisa F. Licitra,Amanda Psyrri,Nabil F. Saba, Natasa Rajicic,Binaifer Balsara,Michael R. Kurman,Catherine Rose Scholz,Antonio Gualberto,Alan Loh Ho

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn